FY2023 · ended Dec 31, 2023 · Revenue $0, -100.0% YoY · Filed Mar 20, 2025
Immuneering Corporation (IMRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$45.5 million. As of Sep 30, 2026 it held $58.2 million in cash and investments and $3.5 million in total debt.
Revenue
$0
-100.0% vs prior year
Net income
$-56.02M
+8.2% vs prior year
Operating cash flow (TTM)
$-61.56M
-23.1% vs year-ago TTM
Free cash flow (TTM)
$-61.81M
-23.5% vs year-ago TTM
EPS
$-1.27
+37.7% vs prior year
Dividend per share
None
Shares outstanding
—
Net cash
$54.69M
as of Sep 30, 2026
Operating margin
-16325.8%
FY 2022
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IMRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1790340
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $316,952 | $2.1M |
| Operating income | -$59.4M | -$64.1M | -$58.4M | -$51.7M | -$33.9M |
| Net income | -$56.0M | -$61.0M | -$53.5M | -$50.5M | -$33.5M |
| Diluted EPS | -$1.27 | -$2.04 | -$1.88 | -$1.91 | -$2.46 |
| Operating cash flow | -$45.3M | -$55.0M | -$49.0M | -$44.1M | -$30.9M |
| Free cash flow | -$45.5M | -$55.1M | -$49.3M | -$44.8M | -$30.9M |
| Total assets | $232.0M | $52.7M | $102.6M | $122.4M | $166.7M |
| Total liabilities | $13.5M | $11.3M | $12.0M | $12.5M | $10.7M |
| Stockholders' equity | $218.5M | $41.4M | $90.6M | $109.9M | $156.0M |
| Cash and investments | $128.6M | $36.1M | $85.7M | $105.5M | $150.2M |
| Total debt | $3.8M | $4.2M | $4.5M | $4.8M | $5.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 15, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 11, 2026 |
All 322 Immuneering Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.